Derleme
BibTex RIS Kaynak Göster

Yıl 2021, Cilt: 38 Sayı: 3, 361 - 366, 01.05.2021

Muhammet Volkan Bülbül Berna Yıldırım Bircan Kolbaşı İlknur Keskin

Öz

Kaynakça

  • Ankrum, J., Karp, J.M., 2010. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends. Mol. Med. 16, 203-9.
  • Artini, P.G., et al., 1996. Growth hormone cotreatment with gonadotropins in ovulation induction. J. Endocrinol. Invest. 19, 763-779.
  • Augello, A., et al., 2005. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35, 1482-1490.
  • Badawy, A., Elnashar, A., 2011. Treatment options for polycystic ovary syndrome. Int. J. Women's Health. 3, 25.
  • Boostanfar, R., et al., 2001. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil. Steril. 75, 1024-1026.
  • Corbould, A., 2008. Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: Are the molecular mechanisms distinct from type 2 diabetes? Panminerva Med. 50, 279-294.
  • Demyda, S., Genero, E., 2011. Developmental competence of in vivo and in vitro matured oocytes: A review. Biotechnol. Mol. Biol. 6, 155-165.
  • Ding, D.-C., et al., 2011. Mesenchymal stem cells. Cell Transplant. 20, 5-14.
  • Divyashree, S., et al., 2019. Experimental models of polycystic ovary syndrome: An update. Life Sci. 237, 116911.
  • Dominici, M., et al., 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 8, 315-317.
  • Ellenbogen, A., et al., 2014. Ivm results are comparable and may have advantages over standard ivf. Facts Views Vis. Obgyn. 6, 77.
  • Elnashar, A., et al., 2006. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: A prospective placebo-controlled study. Hum. Reprod. 21, 1805-1808.
  • Franks, S., et al., 2008. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum. Reprod. Update. 14, 367-378.
  • He, Y., et al., 2018. The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. Stem Cell Res. Ther. 9, 263.
  • Hernigou, P., et al., 1997. Bone-marrow transplantation in sickle-cell disease. Effect on osteonecrosis: A case report with a four-year follow-up. JBJS. 79, 1726-30.
  • Huang, X., et al., 2013. Differences in the transcriptional profiles of human cumulus cells isolated from mi and mii oocytes of patients with polycystic ovary syndrome. Reprod. (Cambridge, England). 145, 597-608.
  • Hwu, Y., et al., 2005. Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int. J. Gynecol. Obstet. 90, 39-43.
  • Ishizuka, Y., et al., 2013. The influence of reduced glutathione in fertilization medium on the fertility of in vitro–matured c57bl/6 mouse oocytes. Theriogenology. 80, 421-426.
  • Jafarzadeh, H., et al., 2018. Improvement of oocyte in vitro maturation from mice with polycystic ovary syndrome by human mesenchymal stromal cell–conditioned media. J. Cell. Biochem. 119, 10365-10375.
  • Jee, B.C., et al., 2008. Influence of well defined protein source on in vitro maturation of human oocyte: Human follicular fluid versus human serum albumin. Fertil. Steril. 89, 348-352.
  • Kalhori, Z., et al., 2018. Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome. Cytotherapy. 20, 1445-1458.
  • Legro, R.S., et al., 2007. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356, 551-566.
  • Li, J., et al., 2015. Estrogen secreted by mesenchymal stem cells necessarily determines their feasibility of therapeutical application. Sci. Rep. 5, 15286.
  • Lim, K.S., et al., 2013. In vitro maturation: Clinical applications. Clin. Exp. Reprod. Med. 40, 143.
  • Lin, C.-Y., et al., 2011. The role of adipose-derived stem cells engineered with the persistently expressing hybrid baculovirus in the healing of massive bone defects. Biomaterials. 32, 6505-6514.
  • Ling, B., et al., 2008. Effect of conditioned medium of mesenchymal stem cells on the in vitro maturation and subsequent development of mouse oocyte. Braz. J. Med. Biol. Res. 41, 978-985.
  • Lizneva, D., et al., 2016. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril. 106, 6-15.
  • Lou, G., et al., 2015. Exosomes derived from mir-122-modified adipose tissue-derived mscs increase chemosensitivity of hepatocellular carcinoma. J. Hematol. Oncol. 8, 1-11.
  • Messinis, I., Nillius, S., 1982. Comparison between tamoxifen and clomiphene for induction of ovulation. Acta Obstet. Gynecol. Scand. 61, 377.
  • Mutlu, L., et al., 2015. The endometrium as a source of mesenchymal stem cells for regenerative medicine. Biol. Reprod. 92,.
  • Nardo, L., 2004. Management of anovulatory infertility associated with polycystic ovary syndrome: Tamoxifen citrate an effective alternative compound to clomiphene citrate. Gynecol. Endocrinol. 19, 235-238.
  • Parsanezhad, M.E., et al., 2002. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: A prospective, double-blind, placebo-controlled trial. Fertil. Steril. 78, 1001-1004.
  • Qu, Y., et al., 2017. Exosomes derived from mir‐181‐5p‐modified adipose‐derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. J. Cell. Mol. Med. 21, 2491-2502.
  • Sam, S., Dunaif, A., 2003. Polycystic ovary syndrome: Syndrome. Trends Endrocrinol. Metab. 14, 365-370.
  • Sánchez, F., et al., 2015. Human cumulus-enclosed germinal vesicle oocytes from early antral follicles reveal heterogeneous cellular and molecular features associated with in vitro maturation capacity. Hum. Reprod. 30, 1396-1409.
  • Shalom-Paz, E., et al., 2012. Pcos patients can benefit from in vitro maturation (ivm) of oocytes. Eur. J. Obstet. Gynecol. Reprod. Biol. 165, 53-56.
  • Stein, I.F., 1935. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181-191.
  • Stener-Victorin, E., et al., 2000. Effects of electro-acupuncture on anovulation in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 79, 180-188.
  • Teede, H., et al., 2010. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41.
  • Wang, T., et al., 2019. Mir-323-3p regulates the steroidogenesis and cell apoptosis in polycystic ovary syndrome (PCOS) by targeting igf-1. Gene. 683, 87-100.
  • Xie, Q., et al., 2019. Mesenchymal stem cells alleviate dhea-induced polycystic ovary syndrome (PCOS) by inhibiting inflammation in mice. Stem Cells Int. 2019,.
  • Xin, H., et al., 2012. Exosome‐mediated transfer of mir‐133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 30, 1556-1564.
  • Yeo, R.W.Y., et al., 2013. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 65, 336-341.
  • Yildiz, B.O., et al., 2012. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. 27, 3067-3073.
  • Yoon, B.S., et al., 2010. Secretory profiles and wound healing effects of human amniotic fluid–derived mesenchymal stem cells. Stem Cells Dev. 19, 887-902.
  • Zhang, X., et al., 2015. Exosomes in cancer: Small particle, big player. J. Hematol. Oncol. 8, 83.
  • Zhao, Y., et al., 2019. Mesenchymal stem cells derived exosomal mir-323-3p promotes proliferation and inhibits apoptosis of cumulus cells in polycystic ovary syndrome (PCOS). Artif. Cells Nanomed. Biotechnol. 47, 3804-3813.
  • Zomer, A., et al., 2010. Exosomes: Fit to deliver small RNA. Commun. Integr. Biol. 3, 447-450.

Mesenchymal stem cell applications in polycystic ovary syndrome treatment

Yıl 2021, Cilt: 38 Sayı: 3, 361 - 366, 01.05.2021

Muhammet Volkan Bülbül Berna Yıldırım Bircan Kolbaşı İlknur Keskin

Öz

Mesenchymal stem cells (MSCs) are highly capable of self-renewal and differentiation. They can be isolated from a variety of sources such as adipose tissue, bone marrow, umbilical cord, tooth pulp and can be cultured under in vitro conditions. MSCs have anti-inflammatory, anti-apoptotic, angiogenic, immunomodulatory and many more therapeutic effects due to the effects of paracrine factors they secrete. Today, mesenchymal stem cells are used for treatment in more than twenty diseases, from spinal cord injuries to diabetes. However, there is little mention in the literature of the use of these cells in female reproductive system diseases. In this review, a limited number of clinical and experimental studies on the use of mesenchymal stem cells in the treatment of polycystic ovary syndrome, which is very common in women, were examined and analyzed.

Anahtar Kelimeler

BM-MSC HUC-MSC AMSC PCOS

Kaynakça

  • Ankrum, J., Karp, J.M., 2010. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends. Mol. Med. 16, 203-9.
  • Artini, P.G., et al., 1996. Growth hormone cotreatment with gonadotropins in ovulation induction. J. Endocrinol. Invest. 19, 763-779.
  • Augello, A., et al., 2005. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35, 1482-1490.
  • Badawy, A., Elnashar, A., 2011. Treatment options for polycystic ovary syndrome. Int. J. Women's Health. 3, 25.
  • Boostanfar, R., et al., 2001. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil. Steril. 75, 1024-1026.
  • Corbould, A., 2008. Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: Are the molecular mechanisms distinct from type 2 diabetes? Panminerva Med. 50, 279-294.
  • Demyda, S., Genero, E., 2011. Developmental competence of in vivo and in vitro matured oocytes: A review. Biotechnol. Mol. Biol. 6, 155-165.
  • Ding, D.-C., et al., 2011. Mesenchymal stem cells. Cell Transplant. 20, 5-14.
  • Divyashree, S., et al., 2019. Experimental models of polycystic ovary syndrome: An update. Life Sci. 237, 116911.
  • Dominici, M., et al., 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 8, 315-317.
  • Ellenbogen, A., et al., 2014. Ivm results are comparable and may have advantages over standard ivf. Facts Views Vis. Obgyn. 6, 77.
  • Elnashar, A., et al., 2006. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: A prospective placebo-controlled study. Hum. Reprod. 21, 1805-1808.
  • Franks, S., et al., 2008. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum. Reprod. Update. 14, 367-378.
  • He, Y., et al., 2018. The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. Stem Cell Res. Ther. 9, 263.
  • Hernigou, P., et al., 1997. Bone-marrow transplantation in sickle-cell disease. Effect on osteonecrosis: A case report with a four-year follow-up. JBJS. 79, 1726-30.
  • Huang, X., et al., 2013. Differences in the transcriptional profiles of human cumulus cells isolated from mi and mii oocytes of patients with polycystic ovary syndrome. Reprod. (Cambridge, England). 145, 597-608.
  • Hwu, Y., et al., 2005. Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int. J. Gynecol. Obstet. 90, 39-43.
  • Ishizuka, Y., et al., 2013. The influence of reduced glutathione in fertilization medium on the fertility of in vitro–matured c57bl/6 mouse oocytes. Theriogenology. 80, 421-426.
  • Jafarzadeh, H., et al., 2018. Improvement of oocyte in vitro maturation from mice with polycystic ovary syndrome by human mesenchymal stromal cell–conditioned media. J. Cell. Biochem. 119, 10365-10375.
  • Jee, B.C., et al., 2008. Influence of well defined protein source on in vitro maturation of human oocyte: Human follicular fluid versus human serum albumin. Fertil. Steril. 89, 348-352.
  • Kalhori, Z., et al., 2018. Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome. Cytotherapy. 20, 1445-1458.
  • Legro, R.S., et al., 2007. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356, 551-566.
  • Li, J., et al., 2015. Estrogen secreted by mesenchymal stem cells necessarily determines their feasibility of therapeutical application. Sci. Rep. 5, 15286.
  • Lim, K.S., et al., 2013. In vitro maturation: Clinical applications. Clin. Exp. Reprod. Med. 40, 143.
  • Lin, C.-Y., et al., 2011. The role of adipose-derived stem cells engineered with the persistently expressing hybrid baculovirus in the healing of massive bone defects. Biomaterials. 32, 6505-6514.
  • Ling, B., et al., 2008. Effect of conditioned medium of mesenchymal stem cells on the in vitro maturation and subsequent development of mouse oocyte. Braz. J. Med. Biol. Res. 41, 978-985.
  • Lizneva, D., et al., 2016. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril. 106, 6-15.
  • Lou, G., et al., 2015. Exosomes derived from mir-122-modified adipose tissue-derived mscs increase chemosensitivity of hepatocellular carcinoma. J. Hematol. Oncol. 8, 1-11.
  • Messinis, I., Nillius, S., 1982. Comparison between tamoxifen and clomiphene for induction of ovulation. Acta Obstet. Gynecol. Scand. 61, 377.
  • Mutlu, L., et al., 2015. The endometrium as a source of mesenchymal stem cells for regenerative medicine. Biol. Reprod. 92,.
  • Nardo, L., 2004. Management of anovulatory infertility associated with polycystic ovary syndrome: Tamoxifen citrate an effective alternative compound to clomiphene citrate. Gynecol. Endocrinol. 19, 235-238.
  • Parsanezhad, M.E., et al., 2002. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: A prospective, double-blind, placebo-controlled trial. Fertil. Steril. 78, 1001-1004.
  • Qu, Y., et al., 2017. Exosomes derived from mir‐181‐5p‐modified adipose‐derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. J. Cell. Mol. Med. 21, 2491-2502.
  • Sam, S., Dunaif, A., 2003. Polycystic ovary syndrome: Syndrome. Trends Endrocrinol. Metab. 14, 365-370.
  • Sánchez, F., et al., 2015. Human cumulus-enclosed germinal vesicle oocytes from early antral follicles reveal heterogeneous cellular and molecular features associated with in vitro maturation capacity. Hum. Reprod. 30, 1396-1409.
  • Shalom-Paz, E., et al., 2012. Pcos patients can benefit from in vitro maturation (ivm) of oocytes. Eur. J. Obstet. Gynecol. Reprod. Biol. 165, 53-56.
  • Stein, I.F., 1935. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181-191.
  • Stener-Victorin, E., et al., 2000. Effects of electro-acupuncture on anovulation in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 79, 180-188.
  • Teede, H., et al., 2010. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41.
  • Wang, T., et al., 2019. Mir-323-3p regulates the steroidogenesis and cell apoptosis in polycystic ovary syndrome (PCOS) by targeting igf-1. Gene. 683, 87-100.
  • Xie, Q., et al., 2019. Mesenchymal stem cells alleviate dhea-induced polycystic ovary syndrome (PCOS) by inhibiting inflammation in mice. Stem Cells Int. 2019,.
  • Xin, H., et al., 2012. Exosome‐mediated transfer of mir‐133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 30, 1556-1564.
  • Yeo, R.W.Y., et al., 2013. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 65, 336-341.
  • Yildiz, B.O., et al., 2012. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. 27, 3067-3073.
  • Yoon, B.S., et al., 2010. Secretory profiles and wound healing effects of human amniotic fluid–derived mesenchymal stem cells. Stem Cells Dev. 19, 887-902.
  • Zhang, X., et al., 2015. Exosomes in cancer: Small particle, big player. J. Hematol. Oncol. 8, 83.
  • Zhao, Y., et al., 2019. Mesenchymal stem cells derived exosomal mir-323-3p promotes proliferation and inhibits apoptosis of cumulus cells in polycystic ovary syndrome (PCOS). Artif. Cells Nanomed. Biotechnol. 47, 3804-3813.
  • Zomer, A., et al., 2010. Exosomes: Fit to deliver small RNA. Commun. Integr. Biol. 3, 447-450.
Toplam 48 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Clinical Research
Yazarlar

Muhammet Volkan Bülbül 0000-0003-1526-2065

Berna Yıldırım 0000-0002-4479-2586

Bircan Kolbaşı 0000-0001-7933-4262

İlknur Keskin 0000-0002-7059-1884

Yayımlanma Tarihi 1 Mayıs 2021
Gönderilme Tarihi 14 Kasım 2020
Kabul Tarihi 16 Aralık 2020
Yayımlandığı Sayı Yıl 2021 Cilt: 38 Sayı: 3

Kaynak Göster

APA Bülbül, M. V., Yıldırım, B., Kolbaşı, B., Keskin, İ. (2021). Mesenchymal stem cell applications in polycystic ovary syndrome treatment. Journal of Experimental and Clinical Medicine, 38(3), 361-366.
AMA Bülbül MV, Yıldırım B, Kolbaşı B, Keskin İ. Mesenchymal stem cell applications in polycystic ovary syndrome treatment. J. Exp. Clin. Med. Mayıs 2021;38(3):361-366.
Chicago Bülbül, Muhammet Volkan, Berna Yıldırım, Bircan Kolbaşı, ve İlknur Keskin. “Mesenchymal Stem Cell Applications in Polycystic Ovary Syndrome Treatment”. Journal of Experimental and Clinical Medicine 38, sy. 3 (Mayıs 2021): 361-66.
EndNote Bülbül MV, Yıldırım B, Kolbaşı B, Keskin İ (01 Mayıs 2021) Mesenchymal stem cell applications in polycystic ovary syndrome treatment. Journal of Experimental and Clinical Medicine 38 3 361–366.
IEEE M. V. Bülbül, B. Yıldırım, B. Kolbaşı, ve İ. Keskin, “Mesenchymal stem cell applications in polycystic ovary syndrome treatment”, J. Exp. Clin. Med., c. 38, sy. 3, ss. 361–366, 2021.
ISNAD Bülbül, Muhammet Volkan vd. “Mesenchymal Stem Cell Applications in Polycystic Ovary Syndrome Treatment”. Journal of Experimental and Clinical Medicine 38/3 (Mayıs 2021), 361-366.
JAMA Bülbül MV, Yıldırım B, Kolbaşı B, Keskin İ. Mesenchymal stem cell applications in polycystic ovary syndrome treatment. J. Exp. Clin. Med. 2021;38:361–366.
MLA Bülbül, Muhammet Volkan vd. “Mesenchymal Stem Cell Applications in Polycystic Ovary Syndrome Treatment”. Journal of Experimental and Clinical Medicine, c. 38, sy. 3, 2021, ss. 361-6.
Vancouver Bülbül MV, Yıldırım B, Kolbaşı B, Keskin İ. Mesenchymal stem cell applications in polycystic ovary syndrome treatment. J. Exp. Clin. Med. 2021;38(3):361-6.
 Kapak Resmi İndir

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.